MedTrace Logo

Evaluation of the Antipruritic Effect of PAC-14028 Cream in Skin Pruritus

NCT02052531 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2015-09-14

No results posted yet for this study

Summary

The objective of this study was to find a clinically appropriate dose of PAC-14028 cream by comparatively evaluating the efficacy and safety of PAC-14028 cream of Amorepacific Corporation in patients with dermal pruritus.

Conditions

  • Skin Pruritus

Interventions

DRUG

PAC-14028

Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks

OTHER

Vehicle

Participants received topical Vehicle twice daily for 4 weeks

Sponsors & Collaborators

  • Amorepacific Corporation

    lead INDUSTRY

Principal Investigators

  • Kyu-Han Kim, MD,Ph.D · Department of Dermatology, Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-06-30
Completion
2013-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02052531 on ClinicalTrials.gov